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Leukemia results from the expansion of self-renewing hematopoietic cells that are thought to contain
mutations that contribute to disease initiation and progression. Studies of the gene expression profiles of
human acute myeloid leukemia samples has allowed their classification based on the presence of translocations
and French-American-British subtypes, but it is not yet clear whether their molecular signatures reflect the
initiating mutations or mutations acquired during progression. To begin to address this question, we examined
the expression profiles of normal murine promyelocyte-enriched samples, nontransformed murine promyelo-
cytes expressing human promyelocytic leukemia-retinoic acid receptor alpha (PML-RAR) fusion gene, and
primary acute promyelocytic leukemia cells. The expression profile of nontransformed cells expressing PML-
RAR was remarkably similar to that of wild-type promyelocytes. In contrast, the expression profiles of fully
transformed cells from three acute promyelocytic leukemia model systems were all different, suggesting that
the expression signature of acute promyelocytic leukemia cells reflects the genetic changes that contributed to
progression. To further evaluate these progression events, we compared two high-penetrance acute promyelo-
cytic leukemia models that both commonly acquire an interstitial deletion of chromosome 2 during progres-
sion. The two models exhibited distinct gene expression profiles, suggesting that the dominant molecular
signatures of murine acute promyelocytic leukemia can be influenced by several independent progression
events.
Several groups have created transgenic mouse models of
acute promyelocytic leukemia (also called M3 acute myeloid
leukemia) with the human promyelocytic leukemia-retinoic
acid receptor alpha (PML-RAR) fusion cDNA placed under
the control of regulatory cassettes that direct expression to
early myeloid cells (6, 8, 11). All of the models have long latent
periods that precede the development of acute promyelocytic
leukemia, and most have been only partially penetrant. These
results suggested that PML-RAR expression is necessary for
acute promyelocytic leukemia development but not sufficient
to cause disease; the long latent period strongly suggests that
additional genetic and/or epigenetic events must occur for leu-
kemia to develop.
The genetic changes that accompany leukemia progression
can be characterized directly, i.e., with cytogenetics, compara-
tive genomic hybridization (27), and/or DNA sequencing (16),
or indirectly, by studying the gene expression profiles of leu-
kemia cells (7, 33); these expression profiles can serve as mark-
ers of specific mutations. For example, acute myeloid leukemia
samples containing specific translocations, e.g., t(15;17), t(8;
21), or inv(16), can be distinguished based on their distinct
expression profiles (13, 26). Although this approach is useful
for distinguishing different types of leukemia, it has been more
difficult to characterize the consequences of mutations that
contribute to disease initiation versus progression because hu-
man acute leukemias are usually detected in the fully trans-
formed state.
In murine acute myeloid leukemia models, however, the
initiation event can be engineered into the germ line, so that
progression events can be studied prospectively. One cytoge-
netically defined progression event has been found to occur
with high frequency in several mouse models of acute myeloid
leukemia; this change is an interstitial deletion of one copy of
mouse chromosome 2, del(2) (18, 28, 34). Importantly, some
patients with relapsed acute promyelocytic leukemia develop
an interstitial deletion of the syntenic region on human chro-
mosome 11p11-13 (3). These two regions display nearly perfect
synteny, which allows straightforward comparisons of poten-
tially relevant genes between species. The deletion of genes on
this interval may therefore be important for leukemia progres-
sion in both mice and humans.
Acute promyelocytic leukemia appears to be different from
other types of acute myeloid leukemia in that the CD34/
CD38 population does not contain the leukemia-initiating
cells (4, 5). In addition, the CD34/CD38 population of acute
promyelocytic leukemia cells does not contain the PML-RAR
transcript that is present in CD34/CD38 cells, suggesting
that more mature cells represent the transformed population
in this disease (30). Since cells with promyelocytic morphology
also accumulate in murine acute promyelocytic leukemia, we
decided to examine the expression profiles of normal murine
promyelocytes, nontransformed promyelocytes that express
PML-RAR, and fully transformed promyelocytes in an at-
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tempt to understand the genetic events that contribute to dis-
ease initiation versus progression.
We report here that normal murine promyelocyte-enriched
samples and promyelocyte-enriched cells expressing PML-
RAR are developmentally similar and contain very similar
gene expression profiles. In contrast, different events that fa-
cilitate the development of acute promyelocytic leukemia can
ultimately yield distinct expression signatures, suggesting that
the expression profiles observed in acute promyelocytic leuke-
mia cells may be due to genetic changes that occurred during
disease progression. Therefore, these acute promyelocytic leu-
kemia signatures appear to mark the consequences of progres-
sion mutations and not the expression of PML-RAR per se.
MATERIALS AND METHODS
Generation of PML-RAR-expressing mice and irradiation parameters. We
have previously described the generation of the human cathepsin G-PML-RAR
transgenic mice (in a C3H  C57BL/6 background, Taconic) (referred to as PR
mice) (8). Age-matched wild-type littermate (WTXRT), PR transgenic mice
(PRXRT), and control wild-type C3H, C57BL/6, and C3H C57BL/6 F1 mice
received 3 Gy of ionizing radiation (XRT; Mark 1 137Cs irradiator) at 8 to 10
weeks of age. The generation and characterization of the doubly transgenic
PML-RAR/RAR-PML mice (referred to as PRRP) have been described (22).
The Washington University Animals Studies Committee approved all animal
experiments.
Analysis of animals, leukemia cryopreservation, flow cytometry, and transfer
of acute promyelocytic leukemia to genetically compatible recipients. Leukemic
mice and leukemic spleen cells from PR and PRXRT transgenic animals were
analyzed as previously described for PRRP mice (22). Acute promyelocytic
leukemia cells from 8 PR and 10 PRRP leukemic mice were previously cryo-
preserved and used in subsequent experiments; 1 PR and 10 PRXRT acute
promyelocytic leukemia samples were harvested from the leukemic mice de-
scribed in this report. Table S1 in the supplemental material contains complete
blood counts, spleen weights, flow cytometry, and cytogenetic information (spec-
tral karyotyping and fluorescence in situ hybridization) for all acute promyelo-
cytic leukemia samples.
All-trans-retinoic acid treatment of acute promyelocytic leukemia cells in
vitro. Cryopreserved leukemic cells were thawed and incubated (106 cells/ml) for
72 h in RPMI 1640 with 10% fetal calf serum supplemented with either 1 M
all-trans-retinoic acid (Sigma, St. Louis, Mo.) dissolved in ethanol or ethanol
alone (0.1% ethanol by volume). Cells were pelleted by centrifugation, and
supernatants were assayed for pro- matrix metalloproteinase 9 levels with the
Quantikine mouse pro- matrix metalloproteinase 9 immunoassay kit protocol
(R&D Systems, Minneapolis, Minn.). Leukemia samples were assayed in at least
two independent experiments.
Interphase fluorescence in situ hybridization. DNA bacterial artificial chro-
mosome probe labeling, hybridization, and posthybridization washes were car-
ried out according to the manufacturer’s recommendations for the nick transla-
tion kit (Vysis, Inc., Downers Grove, Ill.). Chromosome 2 bacterial artificial
chromosome probes included RPCI23-6M16 (located at 7.7 megabases on the
centromeric end of mouse chromosome 2), RPCI23-478G11 (92 megabases),
RPCI23-163L4 (104 megabases), and RPCI23-83A14 (178 megabases on the
telomeric end of chromosome 2).
Generation of an enriched promyelocyte population. Bone marrow cells were
harvested from five wild-type C3H  C57BL/6 mice 2 days after intraperitoneal
injection with 5-fluorouracil (150 mg/kg) (Sigma, St. Louis, Mo.) (19). Total bone
marrow was cultured in Dulbecco’s modified Eagle’s medium containing 20%
fetal calf serum, recombinant murine stem cell factor (100 ng/ml) (R&D Sys-
tems, Minneapolis, Minn.), murine interleukin-3 (6 ng/ml) (R&D Systems, Min-
neapolis, Minn.), murine Flt ligand (50 ng/ml) (R&D Systems, Minneapolis,
Minn.), and human thrombopoietin (10 ng/ml) (PeproTech Inc., Rocky Hill,
N.J.). After 72 h, mononuclear cells were purified by centrifugation on His-
topaque-1077 (Sigma, St. Louis, Mo.). Cells were stained with a lineage cocktail
(B220, CD11b, Gr-1, Ter119, and CD3ε cocktail) (Becton Dickinson, San Jose,
Calif.), and Sca/lineage cells were flow sorted (MoFlo; Cytomation) into
medium that was supplemented with stem cell factor (100 ng/ml) and recombi-
nant human granulocyte colony-stimulating factor (100 ng/ml) (Amgen, Thou-
sand Oaks, Calif.), which induces myeloid differentiation. Total RNA was ex-
tracted from cells harvested on days 0 and 2 to 7 with the RNeasy reagent and
used for quantitative reverse transcription-PCR (Qiagen, Valencia, Calif.). Cy-
tospins were made with cells harvested on days 0 and 2 to 7, and differentials
were performed after May-Grunwald-Giemsa staining (Sigma, St. Louis, Mo.).
Two independent experiments were performed with five wild-type mice in each
group (wild-type day 2 promyelocyte-enriched population). Two independent
experiments were also performed with five PML-RAR transgenic mice in each
group (PR day 2 promyelocyte-enriched population, referred to as PR day 2
promyelocytes).
Expression profiling. Total cellular RNA was purified from two wild-type day
2 promyelocyte samples, two PR day 2 promyelocyte samples, and 27 cryopre-
served leukemia samples with Trizol reagent (Invitrogen, Carlsbad, Calif.) (9 PR,
10 PRRP, and 8 PRXRT acute promyelocytic leukemia samples). Total
RNA was quantitated with a NanoDrop (NanoDrop technologies, Rockland,
Del.) and analyzed for degradation with the RNA LabChip and 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, Calif.). For 9 PR, 10 PRRP, and 8 PRXRT
acute promyelocytic leukemia samples, the Siteman Cancer Center Microarray
Core Facility at Washington University labeled total RNA and hybridized 15 g
of labeled cRNA to the murine Affymetrix U74Av2 array according to the
manufacturer’s instructions (see http://pathbox.wustl.edu/mgacore/genechip
.htm for a complete list of protocols). For two wild-type day 2 promyelocyte
samples and two PR day 2 promyelocyte samples, 6 g of labeled cRNA was
hybridized to the murine Affymetrix U74Av2 arrays. Arrays were generated with
6 g of cRNA because the promyelocyte RNA samples were extracted from
approximately 1  105 to 2  105 cells, yielding smaller amounts of total labeled
cRNA available to hybridize to the arrays. Washes and scanning were carried out
according to the manufacturer’s instructions. In order to perform interarray
comparisons, the data for each array were scaled to a target intensity of 1,500
with Affymetrix Microarray Suite software (see the supplemental material for
MIAME description and http://bioinformatics.wustl.edu for full access to the
primary array data). To address array reproducibility, two arrays were hybridized
with cRNA from the same labeling reaction for acute promyelocytic leukemia
sample 10822.
Chromosomal localization and gene ontology categorization of probe sets on
the U74Av2 array. The accession numbers of all probe sets were used to query
the NCBI Locus Link database for their genomic location and the Gene Ontol-
ogy database for their gene ontology annotation.
Quantitative reverse transcription-PCR. Total RNA was isolated from 27
acute promyelocytic leukemia samples described above. Quantitative reverse
transcription-PCR was performed with SYBR Green (Molecular Probes, Eu-
gene, Oreg.) as previously described (17). All samples were run in duplicate.
Individual cDNA samples were normalized according to their levels of glyceral-
dehhyde-3-phosphate dehydrogenase transcript.
Statistical analysis. Hierarchical clustering was performed with the Decision-
Site for Functional Genomics Spotfire software (Spotfire, Somerville, Mass.).
For this analysis, raw intensity values were normalized and converted to a
z-score. Starting with 12,488 probe sets on the murine U74Av2 array, we ex-
cluded probe sets that were absent in all samples being compared as well as the
Affymetrix control probe sets. For all gene expression profiling comparisons, we
first performed unsupervised hierarchical clustering to investigate potential un-
derlying relationships between samples with an unbiased approach. Subsequent
supervised analysis was performed in order to generate a smaller list of genes and
expressed sequence tags (ESTs) that could be annotated with gene ontology.
Similar sample clustering was preserved for all supervised heat maps compared
to unsupervised hierarchical clustering methods, suggesting that supervised
methods did not falsely create or bias underlying sample clusters.
Probe sets included on supervised lists were selected solely based on statistical
significance (not experimenter hand picking) for inclusion. Unsupervised hier-
archical clustering heat maps were generated with an unweighted average (un-
weighted pairwise group mean average) method with a correlation metric. Un-
supervised clustering results were validated with multiple hierarchical methods
(unweighted pairwise group mean average and complete) and metrics (correla-
tion and cosine correlation), as well as principal component analysis. A probe set
was included in a supervised gene list only if it was identified with both a
nonparametric test (either the Wilcoxon rank sum test for two-group compari-
sons or the Kruskal-Wallis test for three-group comparisons) and the permuta-
tion-based significance analysis of microarrays (SAM) algorithm (31). SAM was
run with the two-class, unpaired parameter or the multiclass parameter, with 100
permutation cycles for all genotypes compared, and the average false discovery
rate for comparisons was 1.84% (0.49 to 4.48%). Heat maps were generated for
supervised gene lists as described for unsupervised hierarchical clustering.
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Promyelocyte-enriched samples from wild-type and PML-
RAR-expressing mice are developmentally similar. To deter-
mine whether PML-RAR directly causes alterations in the
gene expression profiles of primary promyelocytes, we first
needed to enrich these cells. Wild-type promyelocyte-enriched
samples (wild-type day 2 promyelocytes) were generated by
culturing Sca/lineage bone marrow cells from wild-type
C3H  C57BL/6 F1 mice in medium supplemented with stem
cell factor and granulocyte colony-stimulating factor. During
the 7 days following cytokine stimulation, there was a synchro-
nized and orderly expansion of myeloid cells. Cells progressed
from predominant myeloblasts on day 0 to promyelocytes on
days 2 to 3, myelocytes and metamyelocytes on days 4 to 5, and
bands and segmented neutrophils by days 6 to 7 (13a, 19).
Total RNA was extracted from cultured wild-type cells on
days 0 and 2 to 7. Quantitative reverse transcription-PCR was
performed for cathepsin G and neutrophil elastase, two pri-
mary granule genes that are highly expressed in promyelocytes.
Cells removed on day 2 of culture contained the highest levels
of cathepsin G and neutrophil elastase mRNA (13a). The
morphology and primary granule gene expression pattern of
day 2 cultured cells confirmed that the predominant cells in
day 2 cultures are promyelocytes.
Next, we isolated promyelocyte-enriched samples from 8- to
12-week-old nonleukemic PML-RAR-expressing mice (PR
day 2 promyelocytes). The morphology of PR day 2 promyelo-
cytes was similar to that of wild-type day 2 promyelocytes (Fig.
1A and B). With quantitative reverse transcription-PCR, we
determined that the fusion PML-RAR transcript increased
significantly in cells from day 0 to day 2 of culture. Importantly,
PML-RAR protein is present and functional in PR day 2
promyelocytes, since PML is distributed in a microspeckled
pattern in the nuclei of these cells (13a). A major reduction in
cell number occurred in PR cultures on day 3 of culture, while
wild-type cells continued to proliferate (13a). This observation,
in addition to the aforementioned data, necessitated the har-
vesting of PR promyelocytes on day 2.
To perform valid comparisons of the profiles of the promy-
elocyte-enriched populations described above, the populations
analyzed must be developmentally similar. All day 2 cultured
samples contained 86 to 91% early myeloid cells (myeloblasts,
promyelocytes, and myelocytes) (Fig. 1A and B). We also as-
sessed developmental similarity by examining the expression
patterns of myeloid-specific genes. Total RNA was extracted
from two wild-type day 2 promyelocyte cultures and two PR
day 2 promyelocyte cultures, 6 g of labeled cRNA from each
sample was hybridized with the Affymetrix U74Av2 oligonu-
cleotide array, and signal intensity values were scaled to 1,500
to allow interarray comparisons.
The average signal intensity of primary, secondary, and ter-
tiary granule genes from wild-type and PR day 2 promyelocytes
samples was compared (Fig. 1C). The overall pattern of gran-
ule gene expression in PR day 2 promyelocytes was similar to
that of wild-type day 2 promyelocytes. Myeloperoxidase was
the most abundantly expressed granule gene in all samples
(Fig. 1C). Transcripts from genes expressed in mature myeloid
cells (matrix metalloproteinase 9 and CD11b) were called ab-
sent in all samples. The pattern of expression for myeloid
transcription factor genes was also compared for wild-type day
2 promyelocyte and PR day 2 promyelocyte samples. Again,
the pattern of gene expression of PR day 2 promyelocytes was
similar to that of wild-type day 2 promyelocytes (Fig. 1D). The
most abundant myeloid transcription factor mRNA in all sam-
ples was myb, a gene that is known to be expressed in early
myeloid cells. Levels of the transcription factor mRNAs from
the fos and jun genes, which are known to be expressed during
late myeloid development, were called absent.
Finally, only 100 genes/ESTs (1.5% of eligible probe sets)
demonstrated expression levels that changed by twofold or
more between wild-type day 2 promyelocytes and PR day 2
promyelocytes (Fig. 1E; see also Table S2 in the supplemental
material). The SAM algorithm was applied with 6,453 probe
sets from wild-type and PR day 2 promyelocyte samples; 5,969
out of 12,422 probe sets were called absent in all samples and
were excluded from the analysis. The SAM algorithm was
unable to confidently identify probe sets that discriminated
wild-type from PR day 2 promyelocyte samples (all false dis-
covery rates exceeded 13%). These results suggest that PR day
2 promyelocytes are very similar in composition to wild-type
day 2 promyelocytes, based on their similar morphology, sim-
ilar expression patterns of several developmentally regulated
genes, and similar gene expression profiles.
Gene ontology terms were assigned to 6,700 out of 12,422
probe sets on the U74Av2 array, which included 66 out of the
100 genes/ESTs described above. A gene can be classified by
more than one gene ontology term, and therefore a gene may
appear in multiple gene ontology categories. A gene ontology
category was considered significantly overrepresented for a
gene list if at least two genes (representing 10% or more of the
annotated genes on the list) belonged to a category and if the
observed gene frequency for a category occurred more than
expected based on the number of annotated probe sets on the
array. Gene ontology annotation revealed that PML-RAR
expression was associated with the expression of genes active in
the extracellular space (34%, 12 of 35 annotated genes) and
genes that are involved in the inflammatory response (11%),
compared to the expected frequency of these categories (P 
0.05). In contrast, PML-RAR expression was associated with
lower expression of genes that encode cytoplasmic (29%, 9 of
31 annotated genes) or cytoskeleton proteins (13%) and genes
that encode chaperone (10%) or ligase activities (10%) (P 
0.008) (see Table S2 in the supplemental material for a com-
plete gene list and annotation).
Unique gene expression profile for murine acute promyelo-
cytic leukemia cells that express RAR-PML and contain
del(2). We have previously shown that PR mice that also ex-
press an RAR-PML transgene (RP) have a higher penetrance
of disease and usually contain a characteristic interstitial dele-
tion on one copy of chromosome 2, del(2) (34). To determine
whether the PML-RAR/RAR-PML (PRRP) murine
acute promyelocytic leukemia samples exhibit a gene expres-
sion profile similar to that of PR acute promyelocytic leukemia
samples, we harvested RNA from nine acute promyelocytic
leukemia samples without del(2) by spectral karyotyping or
fluorescence in situ hybridization and 10 PRRP acute pro-
myelocytic leukemia samples that were known to contain
del(2) by spectral karyotyping. We hybridized 15 g of labeled
cRNA to the Affymetrix U74Av2 oligonucleotide.
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Differentials of leukemic spleens from PR and PRRP
acute promyelocytic leukemia mice contain at least 70% early
myeloid cells (with a predominance of promyelocytes) (22).
The morphology (see Fig. 4C and D) and cellular composition
of leukemic PR and PRRP spleens were similar (see Fig.
4B). In addition, the pattern of granule gene expression in PR
acute promyelocytic leukemia and PRRP acute promyelo-
cytic leukemia samples was similar, with the primary granule
gene for myeloperoxidase (Mpo) being the most highly ex-
pressed (see Fig. 4F). The myeloid transcription factor gene
expression pattern was also similar in the PR acute promyelo-
cytic leukemia and PRRP acute promyelocytic leukemia
samples, highlighting the similarities of these promyelocytic
leukemias (see Fig. 4G).
Unsupervised hierarchical clustering was performed with
nine PR acute promyelocytic leukemia and 10 PRRP acute
promyelocytic leukemia samples with 7,125 probe sets (repre-
senting 4,759 unique genes and 1,757 ESTs); 5,297 out of
12,422 probe sets were called absent in all 19 samples and were
excluded from the analysis. Three main clusters were apparent,
one with PR acute promyelocytic leukemia samples only (at
the far left of the column dendrogram), one with PRRP
acute promyelocytic leukemia samples only (at the far right),
and a third with a mixture of two PR acute promyelocytic
leukemia and five PRRP acute promyelocytic leukemia sam-
ples (in the center, see Fig. 2A). Overall, the PR acute pro-
myelocytic leukemia and PRRP acute promyelocytic leuke-
mia samples appear to segregate based on the presence or
absence of RAR-PML expression and/or del(2). This sug-
gests the presence of a distinct global gene expression profile in
PRRP samples.
Next, a smaller gene list was generated with supervised
methods in order to investigate potentially important gene
expression patterns associated with PRRP samples. The Wil-
coxon rank-sum test and SAM algorithm were applied to the
7,125 probe sets, and the most highly significant set of genes
common to both tests were identified based solely on the sta-
tistical algorithms. Sixty-five probe sets (representing 53
unique genes and 12 ESTs) were identified that distinguished
PR from PRRP acute promyelocytic leukemia samples. A
heat map was generated with these 65 genes/ESTs in order to
visualize the gene expression differences between the two acute
promyelocytic leukemia models (Fig. 2B).
To test whether the molecular signature defined by the 65
genes/ESTs predicted the presence of del(2), we identified the
genomic locations of the 65 defining genes and/or ESTs. We
were able to identify the exact chromosomal locations of 9,154
probe sets out of 12,422 on the U74Av2 array; 745 of these
mapped to chromosome 2, with 217 located between 85 and
140 megabases (encompassed by cytogenetic bands 2E and 2F,
which was identified as the minimally deleted region by spec-
tral karyotyping in PRRP leukemias) (34); 77 were located
between 85 and 106 megabases (which corresponds to the
FIG. 1. Characterization of wild-type promyelocyte-enriched pop-
ulations and PML-RAR (PR)-expressing promyelocyte-enriched
populations. The morphology of (A) wild-type (WT) day 2 (d2) pro-
myelocytes and (B) PR day 2 promyelocytes (magnification, 1 000).
(C) Affymetrix signal intensity for myeloid granule genes. The myelo-
peroxidase (Mpo), proteinase 3 (Prtn3), lipocalin 2 (Lcn2), lactotrans-
ferrin (Ltf), and proteoglycan (Prg) genes are shown. (D) Affymetrix
signal intensity for myeloid transcription factor genes. (E) Average
expression (Affymetrix signal intensity) for 6,453 probe sets from wild-
type day 2 promyelocytes (n  2) versus PR day 2 promyelocytes (n 
2).
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minimally deleted region on chromosome 2 in radiation-in-
duced murine acute myeloid leukemia mapped by simple se-
quence length polymorphisms) (28). There were 40 genes/
ESTs expressed at lower levels in PRRP acute promyelocytic
leukemia samples with del(2). Ten of these 40 genes/ESTs
mapped to the megabase 85 to 140 region of chromosome 2,
and 6 of these 10 were located between megabases 85 and 106.
This frequency (10 of 40) was significantly greater than the
expected frequency based on the number of del(2) genes
present on the array (P  0.0001). The green bars located at
the left and right sides of the heat map highlight the 10 genes
located on del(2) (Fig. 2B) (see Table S3 in the supplemental
material for a complete gene list and annotation).
Validation of array results was performed with four genes
located within the del(2) interval. Two of these genes were
included in the 10 genes found to be underexpressed in the
PRRP acute promyelocytic leukemia samples (Api5 and
Fbxo3), and two were not (Sfpi1 and Lmo2). Quantitative re-
verse transcription-PCR was performed with 27 acute promy-
elocytic leukemia samples (9 PR, 10 PRRP, and 8
PRXRT), and the results for the four genes correlated sig-
nificantly with the oligonucleotide array results (P 0.05) (Fig.
S1 in the supplemental material).
To determine whether the entire del(2) region was under-
expressed in acute promyelocytic leukemia samples containing
del(2), we calculated the expression ratio of genes across the
entire genome in 10 PRRP acute promyelocytic leukemia
samples with del(2) versus 9 PR acute promyelocytic leukemia
samples without del(2); 5,297 out of 12,422 probe sets were
absent in all samples and excluded from the analysis. The
locations of 5,491 probe sets out of 7,125 eligible probe sets
were mapped to the genome. Proceeding from the centromere
to the telomere of each chromosome, the signal intensity of 50
consecutive genes/ESTs was used to create a log2 PRRP/PR
acute promyelocytic leukemia sample expression ratio for each
genomic interval (Fig. 3A). The average genomic size encom-
passed by 50 consecutive genes/ESTs was 22.7 megabases (2.4
to 49.6 megabases). The centromere of chromosome 1 is lo-
cated at the left of the plot, and the telomere of chromosome
X is at the right. In the center of chromosome 2, four data
points (each point representing 50 consecutive genes/ESTs)
display a decrease in expression in the del(2)-containing sam-
ples, which was more than two standard deviations below the
mean ratio of all data points (Fig. 3A) (average log2 ratio for
the four points decreased on chromosome 2  0.277, confi-
dence interval0.251 to0.303, P 1.78 106 compared
to the remaining data points). These genes map to the mega-
base 70 to 156 interval on chromosome 2, which corresponds to
the minimally deleted region detected by spectral karyotyping
in the PRRP acute promyelocytic leukemia samples. There is
no significant decrease in the average expression ratio for the
corresponding genomic interval when comparing wild-type or
PR day 2 promyelocytes versus PR acute promyelocytic leuke-
mia samples (data not shown).
FIG. 2. Expression profiles of PR versus PRRP acute promyelo-
cytic leukemia samples. (A) Unsupervised hierarchical clustering with
7,125 genes/ESTs (rows) and nine PR acute promyelocytic leukemia
samples without del(2) and 10 PRPR acute promyelocytic leukemia
samples with del(2) (columns). Each row represents one gene/EST,
and each column represents one sample. The genotype and the pres-
ence of an interstitial deletion on chromosome 2 [del(2)] are indicated
at the bottom of each heat map by the presence of a  symbol below
the corresponding sample column. The expression level of each gene
was normalized across all samples and is represented by a color, with
red representing expression above the mean and green representing
expression below the mean, while the color intensity corresponds to
the magnitude of deviation (	) from the mean. The color-coded scale
for normalized expression values for all heat maps is located at the
bottom of the figure. (B) Heat map generated with 65 genes/ESTs
(rows) and 19 samples (columns). Ten genes located on the del(2)
interval, defined by spectral karyotyping (megabases 85 to 140 on
chromosome 2), are highlighted by a green bar to the left and right of
the corresponding row in the heat map. Each row represents one
gene/EST, and each column represents one sample.
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Acute promyelocytic leukemia arising in irradiated PML-
RAR-expressing mice is associated with del(2) and is devel-
opmentally similar to PR and PRRP acute promyelocytic
leukemia. Even though the presence of del(2) is associated
with a striking gene dosage effect, our results do not explain
whether the molecular signature found in PRRP acute pro-
myelocytic leukemia samples is influenced more heavily by
del(2) or by RP expression. To address this question, we had to
develop a second acute promyelocytic leukemia model that
also contains a del(2) gene dosage effect at the genomic level.
We generated a murine acute promyelocytic leukemia model
associated with del(2) by irradiating young PML-RAR-ex-
pressing mice (PRXRT acute promyelocytic leukemia). This
approach was based on the fact that del(2) is the dominant
cytogenetic abnormality associated with radiation-induced mu-
rine acute myeloid leukemia models (9, 10, 20, 25, 28, 29).
We found that 22 of 35 PRXRT mice and 10 of 34 PR
mice developed acute promyelocytic leukemia after a similar
latency of 200 days (67% versus 32%, P  0.0006) (Fig. 4A).
No irradiated wild-type littermate mice in this experimental
cohort developed leukemia. Additional controls were per-
formed with wild-type animals to evaluate potential strain ef-
fects: 1 of 20 C3H, 1 of 20 C57BL/6, and 1 of 20 C3H 
C57BL/6 F1 mice developed acute myeloid leukemia. Leuke-
mic PRXRT mice developed leukocytosis, anemia, thrombo-
cytopenia, and splenomegaly (Table 1). The differential cell
counts (79 
 6% early myeloid cells, n  6) of PRXRT
spleen cells was similar to that of PR acute promyelocytic
leukemia and PRRP acute promyelocytic leukemia samples
(Fig. 4B to E; see also Fig. S2 in the supplemental material).
Intraperitoneal injection of 3  105 to 10  105 cryopreserved
leukemic spleen cells from two separate PRXRT acute pro-
myelocytic leukemia samples into syngeneic recipients caused
uniformly lethal acute promyelocytic leukemia by 60 days.
Cryopreserved leukemic spleen cells from five of five
PRXRT mice demonstrated in vitro differentiation in re-
sponse to 1 M all-trans-retinoic acid treatment (Table 1).
These phenotypic results are highly similar to that observed
with either PR or PRRP leukemic mice (see Table S1 in the
supplemental material). Although the average spleen weight of
PRXRT leukemic mice was less than the average spleen
weight of PR and PRRP leukemic mice (P  0.042 and P 
0.003, respectively), all spleens from leukemic animals were
greatly enlarged compared to age-matched controls (P 
0.002).
Nine out of 10 PRXRT leukemias contained a deletion on
one copy of chromosome 2 that was detected by fluorescence
in situ hybridization (Table 1; see also Fig. S3 in the supple-
mental material); this frequency is similar to the 11 of 13
PRRP leukemias that contained del(2) by spectral karyotyp-
ing (34). In four of four PRXRT leukemias evaluated with
two fluorescence in situ hybridization probes (in addition to
centromeric and telomeric probes), the deletion was interstitial
and spanned at least from megabases 92 to 104 (which is
contained within the minimally deleted region reported for
radiation-induced murine acute myeloid leukemia). One of six
cryopreserved PR acute promyelocytic leukemia samples con-
tained del(2) by fluorescence in situ hybridization, which is
consistent with previously reported spectral karyotyping results
showing that one of five PR acute promyelocytic leukemia
samples contained del(2) (34); neither PR sample with del(2)
was included in this study.
Acute promyelocytic leukemia cells from the two del(2)-
associated models have distinct expression profiles. To ad-
dress whether the presence of del(2) dominantly influences the
molecular signature found in del(2)-associated acute promy-
elocytic leukemia, we examined the expression signature in
del(2)-associated PRXRT samples. Total RNA was ex-
tracted from eight PRXRT acute promyelocytic leukemia
samples; 15 g of labeled cRNA was hybridized to the Af-
fymetrix U74Av2 oligonucleotide array. The average signal
intensity of granule genes from PRXRT acute promyelocytic
FIG. 3. Average expression levels for genes by chromosome in
PRRP and PRXRT acute promyelocytic leukemia samples relative
to PR acute promyelocytic leukemia samples. (A) We mapped 5,491
genes/ESTs to an exact genomic location. The average gene expression
level was calculated for 10 PRRP acute promyelocytic leukemia
samples with del(2) and nine PR acute promyelocytic leukemia sam-
ples without del(2). A PRRP/PR acute promyelocytic leukemia sam-
ple ratio was generated for each gene/EST. The log2 value of each ratio
was calculated, and the log2 ratio for 50 consecutive genes on the same
chromosome was averaged to generate one data point. The last data
point at the right of the plot represents the average log2 expression
ratio for all probe sets unable to be assigned a genomic location
(unknown, n 1,634). (B) We mapped 5,407 genes/ESTs to a genomic
location. Each data point represents the average log2 ratio of 50 con-
secutive genes on a chromosome for 8 PRXRT acute promyelocytic
leukemia samples with del(2) versus nine PR acute promyelocytic
leukemia samples without del(2). The last data point at the right of the
plot represents the average log2 expression ratio for all probe sets
unable to be assigned a genomic location (unknown, n  1,586).
Vertical lines separate chromosomal boundaries. Circles highlight the
data points located on the del(2) interval that are expressed at signif-
icantly lower levels in PRRP and PRXRT acute promyelocytic
leukemia samples compared to PR acute promyelocytic leukemia sam-
ples.
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leukemia samples was compared to PR acute promyelocytic
leukemia and PRRP acute promyelocytic leukemia samples
and was similar (Fig. 4F); the myeloid transcription factor
expression pattern was also similar to that of the PR and
PRRP acute promyelocytic leukemia samples (Fig. 4G). The
log2 PRXRT/PR acute promyelocytic leukemia sample ex-
pression ratio for 50 consecutive genes/ESTs located across the
genome was plotted for eight del(2)-containing PRXRT
acute promyelocytic leukemia samples. In the center of chro-
mosome 2, three out of four consecutive bins of genes/ESTs
displayed a decrease in expression that was greater than two
standard deviations below the mean (Fig. 3B) (average ratio
for the four bins  0.277, confidence interval  0.211 to
0.344, and P  0.003 compared to the remaining bins). This
FIG. 4. Characterization of leukemia arising in irradiated PML-RAR-expressing mice (PRXRT) and comparison to PRRP and PR acute
promyelocytic leukemia samples. (A) Kaplan-Meier survival plot of irradiated wild-type littermate mice (WTXRT), PR mice, and irradiated PR
mice (PRXRT). (B) Flow cytometric results for leukemic spleen cells stained with Gr-1 and CD34 antibodies. Wild-type (WT) (n 8), PR acute
promyelocytic leukemia (APL) (n  9), PRRP acute promyelocytic leukemia (n  10), and PRXRT acute promyelocytic leukemia (n  8)
samples. The morphology of (C) PR, (D) PRRP, and (E) PRXRT acute promyelocytic leukemia cells is shown (magnification, 1,000).
(F) Affymetrix signal intensity for myeloid granule genes. (G) Affymetrix signal intensity for myeloid transcription factor genes.
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area maps to the same region identified in PRRP samples
with del(2).
Unsupervised hierarchical clustering with 6,993 probe sets
(representing 4,691 unique genes and 1,689 ESTs) discrimi-
nated PR acute promyelocytic leukemia samples from
PRXRT acute promyelocytic leukemia samples (Fig. 5A);
5,429 out of 12,422 probe sets were absent in all samples and
excluded from the analysis. To determine whether the most
significant discriminating set of genes for PRXRT acute pro-
myelocytic leukemia samples was also related to a del(2) gene
dosage effect, the top 85 probe sets (representing 68 unique
genes and 14 ESTs) were identified by both the Wilcoxon rank
sum test and SAM to be significantly associated with either PR
or PRXRT acute promyelocytic leukemia samples. Only one
of 85 probe sets was also included in the 65-gene/EST super-
vised list used to discriminate PR versus PRRP acute pro-
myelocytic leukemia samples. A heat map was generated with
these 85 genes/ESTs in order to visualize the gene expression
differences between the two acute promyelocytic leukemia
models (Fig. 5B).
Of the 23 probe sets that exhibited lower expression in
PRXRT acute promyelocytic leukemia samples, only one
was located on chromosome 2 between megabases 85 and 140
(highlighted by a green bar in Fig. 5B), and none was located
on chromosome 2 between megabases 85 to 106 (see Table S4
in the supplemental material for a complete gene list and
annotations). This was not significantly different from the num-
ber of chromosome 2 genes that were expected to be included
in a random list of 23 genes (P  0.05). Furthermore, the 1 of
23 discriminatory genes located on the del(2) interval in the
PRXRT acute promyelocytic leukemia samples was signifi-
cantly less than the 10 of 40 found in the PRRP samples (P
0.044). Therefore, the presence of del(2) in PRXRT acute
promyelocytic leukemia samples did not predict that the most
significant set of defining genes would be del(2) related.
Expression profiles from acute promyelocytic leukemia tu-
mors without del(2). We wished to determine whether leuke-
mias without del(2) had expression profiles that were distinct
from del(2) leukemia samples. Unsupervised hierarchical clus-
tering was performed with 9 PR acute promyelocytic leukemia
samples without del(2), 10 PRRP acute promyelocytic leu-
kemia samples with del(2), and 8 PRXRT acute promyelo-
cytic leukemia samples with del(2), with 7,350 probe sets (rep-
resenting 4,878 unique genes and 1,824 ESTs); 5,072 out of
12,422 probe sets were absent in all 27 samples and were
excluded from the analysis. PR, PRRP, and PRXRT acute
promyelocytic leukemia samples all contained unique gene
signatures (Fig. 6A). In addition, the PR leukemias tended to
cluster with either PRRP or PRXRT acute promyelocytic
leukemia samples. Overall, the acute promyelocytic leukemia
samples did not appear to segregate based on the presence or
absence of del(2), implying that additional non-del(2) progres-
sion events also influence the global gene expression pattern in
acute promyelocytic leukemia samples. A similar pattern of
acute promyelocytic leukemia sample segregation was ob-
served with a principal component analysis method (see Fig. S4
in the supplemental material). Collectively, these unsupervised
clustering approaches suggested that del(2) status alone does
not predict the global expression signature for acute promy-
elocytic leukemia samples.
The acute promyelocytic leukemia sample clusters identified
with unsupervised approaches were generated without a priori
input or knowledge of a “correct” answer. These findings are
further supported by results obtained with supervised methods
(an approach that successfully discriminated PR from PRRP
and PR from PRXRT acute promyelocytic leukemia sam-
ples). With the Kruskal-Wallis test and SAM algorithm, we
identified the 62 most significant probe sets (representing 48
unique genes and 11 ESTs) that defined the 9 PR, 10 PRRP,
and 8 PRXRT acute promyelocytic leukemia samples from
each other; 5,072 probe sets were absent in all 27 samples and
were excluded from the analysis. The heat map generated with
these 62 genes/ESTs was remarkably similar to the unsuper-
vised hierarchical clustering visualization (Fig. 6B).
Gene ontology annotation was available for 38 of the 62
defining probe sets. Twenty-nine of the 42 highly expressed
genes in PRXRT and 4 PR acute promyelocytic leukemia
samples were classified, and 14 of 29 (48%) encode proteins
active in the nucleus (Fig. 6B, blue dots) involved in DNA
(38%) or ATP binding (24%) (Fig. 6B, red dots) (P  0.05).
Eight of the 18 genes that were expressed at higher levels in
PRRP and five PR acute promyelocytic leukemia samples
were classified, and four of eight (50%) genes are involved in
RNA splicing and elongation (Fig. 6B, green dots) (P  0.05).
One of the two genes expressed at higher levels in the nine PR
acute promyelocytic leukemia samples was located on the


















15557 39.48 5.00 161 0.770 33/50 0/50 66 ND
15794 47.84 8.50 169 0.800 72/100 10/100 82 ND
16079 61.60 14.20 259 1.230 66/100 18/100 84 
17194 28.08 8.30 91 0.490 37/50 3/50 80 
17738 30.86 11.70 597 0.810 10/50 0/50 20 
17749 21.22 7.80 344 1.060 42/50 2/50 88 ND
17755 76.28 6.20 296 0.770 39/50 0/50 78 
17836 24.22 7.10 421 0.870 0/50 0/50 0 ND
17845 16.24 5.20 171 0.570 35/50 11/50 92 ND
17849 23.78 4.00 91 0.500 45/50 3/50 96 
Avg 36.96 7.80 260 0.787 69
a , myeloid differentiation; ND, not done.
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del(2) interval. (see Table S5 in the supplemental material for
a complete gene list and annotation).
DISCUSSION
In this report, we examined the gene expression profiles of
wild-type murine promyelocyte-enriched populations, promy-
elocyte-enriched populations from nonleukemic PML-RAR
(PR)-expressing mice, and leukemic promyelocytes from three
murine acute promyelocytic leukemia models. The gene ex-
pression profiles present in acute promyelocytic leukemia
models were dramatically different from each other, in contrast
to the similar expression profiles seen for wild-type and non-
leukemic, PR-expressing day 2 promyelocyte-enriched popula-
tions. Although the gene expression profile for del(2)-associ-
ated PRRP acute promyelocytic leukemia samples was
strongly associated with the loss of one copy of the genes on
the del(2) interval, the presence of del(2) did not predict a
similar expression profile in an irradiation-induced del(2)
acute promyelocytic leukemia model. The molecular hetero-
geneity observed in these murine acute promyelocytic leuke-
mia models strongly suggests that del(2) is one of several
genetic events that can synergize with PML-RAR to cause
progression.
Thorough cellular characterization of the samples being
compared by gene expression profiling is necessary to deter-
mine whether any observed differences are simply a reflection
of cellular differences between samples or preparation arti-
facts. The method used to enrich promyelocytes in this study
represents the best currently available technique for the study
of primary murine myeloid cells. We demonstrated that the
composition of enriched promyelocytes was highly similar;
based on morphology and the overall expression patterns of
early versus late myeloid genes and transcription factor genes
(Fig. 1). The same rigorous characterization parameters were
used to compare the cellular composition of all of the acute
promyelocytic leukemia models (Fig. 4). Therefore, our data
strongly suggests that the expression profiling differences noted
between the acute promyelocytic leukemia samples probably
reflect genetic differences among these samples, not cellular
ones.
Wild-type day 2 promyelocytes, PR day 2 promyelocytes,
and PR acute promyelocytic leukemia cells are morphologi-
cally similar and have similar expression patterns of myeloid
transcription factors and granule genes (Fig. 1 and 4). Despite
this, direct comparison of the expression profiles from these
cells is difficult to interpret because the culture conditions
required to generate the promyelocyte-enriched samples could
potentially alter their global gene expression pattern. Aware of
this limitation, we directly compared promyelocyte-enriched
samples and PR acute promyelocytic leukemia samples. With
unsupervised hierarchical clustering, the expression profiles of
wild-type and PR day 2 promyelocytes were highly similar, and
both were very different from that of the PR acute promyelo-
cytic leukemia samples (see Fig. S5 in the supplemental mate-
rial). This finding may reflect cellular differences between sam-
ples, or the expression profiles may reflect real genetic
differences among these samples. Direct evidence supporting
this hypothesis will require novel experimental methods (yet to
be described) that allow the isolation of cells from all samples
with identical conditions.
To address the direct effects of PML-RAR expression in
primary early myeloid cells, we compared expression profiles
from wild-type versus PR day 2 promyelocytes. Importantly,
PML oncogenic domains are intact in day 0 cells but are fully
disrupted in PR day 2 promyelocytes (13a), which shows that
PML-RAR is activated and functional on day 2 of culture.
FIG. 5. Expression profiles of PR versus PRXRT acute promy-
elocytic leukemia samples. (A) Unsupervised hierarchical clustering
with 6,993 genes/ESTs (rows) and nine PR acute promyelocytic leu-
kemia samples without del(2) and eight PRXRT acute promyelocytic
leukemia samples with del(2) (columns). (B) Heat map generated with
85 genes/ESTs (rows) and 17 samples (columns). One gene located on
the del(2) interval, defined by spectral karyotyping (megabases 85 to
140 on chromosome 2), is highlighted by a green bar at the left and
right of the corresponding row in the heat map. Each row represents
one gene/EST, and each column represents one sample.
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FIG. 6. Expression profiles of PR, PRRP, and PRXRT acute promyelocytic leukemia samples. (A) Unsupervised hierarchical clustering
with 7,350 genes/ESTs (rows) and nine PR acute promyelocytic leukemia samples without del(2), 10 PRRP acute promyelocytic leukemia
samples with del(2), and eight PRXRT acute promyelocytic leukemia samples with del(2) (columns). (B) Heat map generated with 62
genes/ESTs (rows) and 27 samples (columns). Each row represents one gene/EST, and each column represents one sample.
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Despite this, the expression of only 1.5% of genes/ESTs (100
total) was altered by twofold or more between wild-type day 2
promyelocytes and PR day 2 promyelocytes, which shows that
PML-RAR expression does not cause widespread gene ex-
pression changes in primary cells. Although a difference in 100
genes/ESTs was slightly higher than the number of changed
genes observed for duplicate array experiments (1.1%, P 
0.02), only 22 of 100 genes/ESTs changed threefold or more. In
addition, these 100 probe sets do not overlap with the probe
sets that discriminate the acute promyelocytic leukemia sam-
ples from each other (0 of 65 PR versus PRRP, 0 of 85 PR
versus PRXRT, and 1 of 62 PR versus PRRP versus
PRXRT discriminatory probe sets were included in the list of
100 genes/ESTs, proportions not significantly different than
chance alone, P  0.05).
The small gene expression changes observed in primary cells
are supported by the modest changes recently reported for
parental U937 cells compared to PR-9 cells induced to express
PR for 8 or 16 h (1, 21). Perhaps not surprisingly, our list of 100
potential target genes does not overlap those reported previ-
ously. This may reflect the differences in the cellular compart-
ment used to express PR (primary early myeloid cells versus
adapted cell lines), the timing and level of PR expression,
species differences (mouse versus human), array probe set rep-
resentation, and experimental design. Further evaluation of
potential PR target genes will require extensive experimenta-
tion and in vivo validation. Regardless, these results suggest
that expression of PR in early myeloid cells does not cause
large changes in gene expression and imply that the altered
expression profile of acute promyelocytic leukemia cells is
more likely due to additional changes acquired during progres-
sion.
Although del(2) may facilitate acute promyelocytic leukemia
progression, it is clearly not required, since most acute promy-
elocytic leukemia tumors arising in PR-expressing mice do not
have it (12, 14, 15, 34). Del(2) can occur in murine bone
marrow cells within days of sublethal irradiation (2, 24), but
only 25% (or less) of mice develop acute myeloid leukemia
after a latency of approximately 12 months (9, 10, 20, 25, 28,
29). These observations suggest that leukemic progression can
be influenced by the presence of del(2), but that additional
events are also necessary—and these events may be the ones
that predict the gene expression profile.
To test this possibility, we used unsupervised hierarchical
clustering and principal component analysis methods to exam-
ine the clustering of acute promyelocytic leukemia samples
with or without del(2). The results suggested that specific ex-
pression signatures were associated with each genotype (PR,
PRRP, and PRXRT), but the clusters were not associated
only with del(2) status (Fig. 6A). This was confirmed with a
smaller list of genes identified by a supervised approach (Fig.
6B). The results suggest that the gene expression profiles of
PR-expressing cells are influenced by facilitators of del(2) for-
mation (RP and XRT) and also by other genetic events that
are apparently shared between del(2) and non-del(2) leuke-
mias (Fig. 6A and B). Myeloid cells expressing PML-RAR
can therefore progress towards acute promyelocytic leukemia
via one of several routes. Even in the presence of del(2), our
data suggest that additional mutations are required for full
transformation to occur (34). PR-expressing cells may acquire
similar mutations in the absence of del(2), but they are less
likely to occur (based on the lower penetrance of disease in
unmanipulated PR mice).
Gene ontology annotation suggests that the facilitated path-
way mutations lead to changes in nuclear (DNA and ATP
binding) or RNA splicing and elongation gene expression, but
the data also suggests that these facilitators are not required
for these pathways to be engaged. We do not yet know whether
these defining gene signatures are causally linked to progres-
sion or simply markers of it. Likewise, we do not yet know
whether del(2) alone can facilitate acute promyelocytic leuke-
mia progression in PR-expressing mice. The generation of a
genetically engineered mouse lacking the del(2) interval will be
required to address this question; our results predict that it
would indeed synergize with PR and cause increased pen-
etrance of murine acute promyelocytic leukemia.
In summary, our results show that the heterogeneity in gene
expression profiles for various murine acute promyelocytic leu-
kemia models is influenced by known secondary genetic events,
i.e., del(2), and additional (as yet undefined) genetic events.
The del(2) gene dosage effect associated with murine acute
promyelocytic leukemia is similar to the gene dosage effects
observed for trisomy 8 and deletions of 5q associated with
human acute myeloid leukemia, suggesting that leukemia pro-
gression may be directly related to the gain or loss of a gene(s)
on these intervals (23, 32). Although the presence of del(2)
does not predict a single, dominant gene expression profile in
murine acute promyelocytic leukemia, these findings warrant
further investigation of genes on the del(2) interval. Insights
gained from the study of murine del(2) may also help us to
understand human acute promyelocytic leukemia cells that
contain the syntenic 11p11-13 deletion.
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